Sulforaphane treatment for autism spectrum disorder: A systematic review

Authors

  • Greer McGuinness Central Michigan University, 207 Wightman Hall, 1202 S. Washington Street, Mount Pleasant, MI 48859, U S A; E-mail: greer.mcguinness@gmail.com
  • Yeonsoo Kim Central Michigan University, 207 Wightman Hall, 1202 S. Washington Street, Mount Pleasant, MI 48859, U S A

DOI:

https://doi.org/10.17179/excli2020-2487

Keywords:

sulforaphane, Autism Spectrum Disorder, glucosinolates, treatment, CAM

Abstract

Autism Spectrum Disorder (ASD) is defined as a neurodevelopmental condition characterized by social communication impairment, delayed development, social function deficit, and repetitive behaviors. The Center for Disease Control reports an increase in ASD diagnosis rates every year. This systematic review evaluated the use of sulforaphane (SFN) therapy as a potential treatment option for individuals with ASD. PubMed.gov, PubMed Central, Natural Medicines, BoardVitals, Google Scholar and Medline were searched for studies measuring the effects of SFN on behavior and cognitive function. All five clinical trials included in this systematic review showed a significant positive correlation between SFN use and ASD behavior and cognitive function. The current evidence shows with minimal side effects observed, SFN appears to be a safe and effective treatment option for treating ASD.

Published

2020-06-26

How to Cite

McGuinness, G., & Kim, Y. (2020). Sulforaphane treatment for autism spectrum disorder: A systematic review. EXCLI Journal, 19, 892–903. https://doi.org/10.17179/excli2020-2487

Issue

Section

Review articles